Pharming Group N.V. (PHAR)
|Net Income (ttm)||40.67M|
|Trading Day||January 22|
|Day's Range||13.97 - 14.50|
|52-Week Range||13.97 - 16.70|
Pharming Group N.V. (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ("ADSs") have been admitted for listing on the Nasdaq Global Market ("Nasdaq") u...
Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ordinary Shares on Nasdaq Global Market
Pharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unm...
Pharming Group N.V. has filed to go public with an IPO on the NASDAQ.
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as ... [Read more...]
Research and Development in Biotechnology
Sijmen de Vries
|Stock Exchange |
|Ticker Symbol |
In 2019, Pharming Group's revenue was 169.02 million, an increase of 25.08% compared to the previous year's 135.13 million. Earnings were 36.20 million, an increase of 44.82%.